The latest funding is a sign of how seriously the Biden administration appears to be taking the pandemic threat.

The misery of the common stomach flu may be coming to an end. Pharmaceutical company Moderna has launched a large-scale Phase ...

Moderna has been awarded approximately $590 million from the federal government to help speed up the development of an ...

Cases of norovirus infections are surging, but coming up with a way to prevent them has proven to be a challenge.

Moderna cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow adoption of its respiratory syncytial virus (RSV) ...

While the headline numbers don't inspire much confidence, Moderna is a stock that deserves a closer look. The company still ...

FILE - A local resident receives the Moderna COVID-19 vaccine shot at a center, June 30, 2021, in the Sumida ward of Tokyo.

The company's newer product, an RSV ( respiratory syncytial virus) vaccine, has also underperformed, contributing "minimal ...

As Moderna (NASDAQ: MRNA) looks to shore up its business in the wake of its declining coronavirus vaccine sales, it's natural ...

Shares of Moderna plunged 20% Monday after the vaccine maker slashed its forecast of full-year 2025 revenue, as sales of its ...

Stéphane Bancel, CEO of mRNA specialist Moderna, delivered some difficult truths to shareholders about the company’s ...